Nanoparticle Vaccines for Immunotherapy: From Design to Clinical Trials

Achraf Noureddine, Jonas G. Croissant, Harrison O. Davis, Lorenza I. Friedrich, Rita E. Serda

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Nanoparticles have the capacity to activate the immune system, based on both intrinsic particle characteristics and through the delivery of immune activating cargo. Co-delivery of antigens with adjuvants, such as cytokines, cytotoxic agents or pathogen-associated molecular patterns, presents opportunities for stimulating antigen-specific immune responses. This chapter highlights the immunogenic benefits of select chemotherapeutics and the use of nanoparticles to deliver immunogenic molecules and antigens. The influence of intrinsic nanoparticle properties and biological barriers on immune responses to nanoparticles is also discussed. In closing, a summary of nanoparticles approved for clinical use in the United States and examples of those approved in other countries are presented to highlight successes in nano-immunotherapy.

Original languageEnglish (US)
Title of host publicationAAPS Advances in the Pharmaceutical Sciences Series
PublisherSpringer
Pages177-204
Number of pages28
DOIs
StatePublished - 2020

Publication series

NameAAPS Advances in the Pharmaceutical Sciences Series
Volume41
ISSN (Print)2210-7371
ISSN (Electronic)2210-738X

Keywords

  • Adjuvant
  • Cancer
  • Delivery
  • Immunotherapy
  • Nanomedicine
  • Nanoparticle vaccine

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Nanoparticle Vaccines for Immunotherapy: From Design to Clinical Trials'. Together they form a unique fingerprint.

Cite this